98%
921
2 minutes
20
Purpose: To compare the effect of orbital floor (OFTA) or intravitreal (IVTA) administration of triamcinolone acetonide on visual acuity and chronic cystoid macular edema (CME) in patients with uveitis.
Methods: Retrospective study of patients suffering from chronic noninfectious uveitis in whom CME (n = 97) did not respond to systemic corticosteroids and/or immunosuppression combined with acetazolamide. Patients received a single injection of either IVTA (n = 48, group 1) or OFTA (n = 49, group 2). Best-corrected visual acuity, macular edema (fluorescein angiography), uveitis activity, ocular hypertension, and cataract formation were analyzed over the course of 1 year.
Results: Improvement in visual acuity (> or = 2 lines, LogMAR) was noted in 50% (IVTA) and 34% (OFTA) after 3 months (p = 0.23), and in 18% (IVTA) and 20% (OFTA) after 12 months. CME improved in 100% (IVTA) and 76% (OFTA) of the eyes within the first month postoperatively (p = 0.36). Macular edema was reduced in 100% (group 1) and 20% (group 2) after 3 months (p < 0.01). At 1 year, cataract progression was noted in 68% (IVTA) and 27% (OFTA) (p < 0.01). Increased intraocular pressure (>21 mm Hg) was detected in 21% (IVTA) and 0% (OFTA) at 4 weeks (p < 0.01) after injection.
Conclusion: Uveitic CME and visual acuity not responding to systemic immunosuppression and acetazolamide may improve after an IVTA and OFTA injection. The effect is mostly transient. While the IVTA injections were more effective for improving CME, ocular hypertension and cataracts developed more often.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000220600 | DOI Listing |
Retin Cases Brief Rep
October 2024
Eye Clinic, Humanitas-Gradenigo Hospital, Torino, Italy.
Purpose: To study the efficacy and safety of pro re nata regimen of brolucizumab, without loading dose, in treatment-naive patients with neovascular age-related macular degeneration (nAMD).
Case Series: Retrospective, observational study. We included all consecutive patients diagnosed with treatment- naïve nAMD undergoing Brolucizumab in Humanitas eye clinic, Turin, Italy between April 2022 and May 2023.
J Ophthalmic Vis Res
September 2025
Clinical Research Development Unit, Shafa Hospital, Kerman University of Medical Sciences, Kerman, Iran.
Purpose: To evaluate the time required for refractive error (RE) stabilization after standard phacoemulsification cataract surgery and identify preoperative factors influencing this duration.
Methods: This prospective case series study enrolled patients who had undergone phacoemulsification cataract surgery. RE stabilization was defined as 0.
Front Med (Lausanne)
August 2025
Eye Center, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Purpose: To investigate the mechanism, intraoperative characteristics, management, and prevention of incision capsular bag herniation (ICBH), a previously unreported complication during cataract surgery in eyes with lens subluxation.
Methods: A retrospective observational case series was conducted on five male patients who developed ICBH during phacoemulsification with intraocular lens (IOL) implantation between January 2019 and December 2024. Among 867 subluxated-lens surgeries performed during this period, the estimated incidence of ICBH was 0.
Clin Ophthalmol
September 2025
Department of Ophthalmology and Optometry, Medical University of Vienna, Vienna, Austria.
Purpose: To compare postoperative astigmatism and visual acuity (VA) outcomes in patients undergoing penetrating keratoplasty (PK) using a liquid-interface femtosecond laser (LI-fs) trephination and a conventional vacuum-trephine (VT) technique.
Methods: Our single-center, retrospective data analysis included 121 eyes (121 patients) treated between April 2014 and November 2022. Patients received PK either with a LI-fs or a VT system.
Clin Ophthalmol
September 2025
Università degli studi di Milano, Milan, Italy.
Purpose: To report clinical outcomes in patients implanted with an isofocal optic-design intraocular lens (IOL) with double C-loop haptics following cataract surgery.
Methods: This was a multicentre-prospective-study involving 108 eyes (54 subjects) implanted with the Isopure Serenity (BVI, Inc). IOL.